Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
Business Wire•10/11/2026•07:00 ET
0
Key Highlights
- ➤Natera and Incyte launch phase II colorectal cancer clinical collaboration
- ➤INCA33890 study targets stage 2/3 CRC patients after surgery and chemotherapy
- ➤Signatera MRD testing guides eligibility and serves as primary and secondary endpoint
- ➤Natera will provide trial matching based on MRD status and eligibility criteria
Expert Statements
Eric Matthews, General Manager, BioPharma, Natera
“We are excited by Incyte’s vision for this innovative trial, leveraging both our extensive real-world evidence and proven MRD capabilities”
Eric Matthews, General Manager, BioPharma, Natera
“Across a growing portfolio of TOMR studies, Signatera has been shown to enable early identification of patients at elevated risk of recurrence and supports enrollment into trials with treatment strategies that may alter the course of disease before radiographic progression occurs.”
Lois Erskine, Vice President and INCA 33890 Global Program Head, Incyte
“Patients with colorectal cancer who remain MRD-positive after surgery and chemotherapy represent a population with substantial unmet need and a significantly elevated risk of recurrence”
Lois Erskine, Vice President and INCA 33890 Global Program Head, Incyte
“We look forward to the valuable insights this collaboration will enable as we work to advance this promising treatment and aim to improve outcomes for patients with CRC.”
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
Trial designed to improve outcomes through Signatera™-guided Treatment on MRD (TOMR), identifying high-risk patients for curative-intent treatment
Get started
Create a free account to read the full story.